Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 26, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 426,462 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,250 pence per share; lowest price paid was 1,244 pence per share.
- Treasury Shares Held: 493,224,284 shares (representing 8.72% of total issued share capital and 9.55% of total voting rights).
- Shares in Issue: 5,162,745,050 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 426,462 repurchased shares. This action increased the proportion of Treasury shares held by the Company relative to the total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of Treasury shares held (493,224,284) against subsequent filings to track ongoing buyback activity.
- Confirm the denominator for voting rights calculations (5,162,745,050 shares) when assessing shareholder notification thresholds.
- Review the Annual General Meeting minutes from May 6, 2010, to understand the full scope of the share repurchase authority utilized.